Adagene, City of Hope Launch Phase 1 Muzastotug/Ivonescimab Trial in MSS Colorectal Cancer
ADAG is trading near its 52-week low of $1.418 (13% above the low) on elevated volume (3.6× avg).
Summary
Adagene and City of Hope opened an investigator-initiated Phase 1 trial testing muzastotug (ADG126) plus ivonescimab in up to 36 patients with advanced MSS colorectal cancer, with chemotherapy combinations planned as later steps.
Key Events · Product Development and Regulatory · ADAG
-
City of Hope Phase 1 Trial Opens
An investigator-initiated Phase 1 will enroll up to 36 patients with advanced microsatellite stable colorectal cancer to test ivonescimab plus muzastotug (ADG126).
-
No Sponsor Cost to Adagene
The study is physician-designed and led by City of Hope, so Adagene funds no trial costs while gaining independent data on its lead asset.
-
Chemotherapy Combinations Planned
After dose optimization, investigators plan to add 5-FU and then irinotecan, aiming at maintenance and first-line metastatic CRC settings.
-
Third PD-1 Bispecific Combination
Adagene said this is the third clinical program pairing muzastotug or ADG126 with a next-generation PD-1 bispecific.
Analysis · ADAG · Life Sciences
A third-party academic cancer center is opening a Phase 1 trial pairing Adagene's lead asset muzastotug with ivonescimab, an investigational PD-1/VEGF bispecific, in up to 36 patients with advanced microsatellite stable colorectal cancer. Because the study is investigator-initiated, Adagene bears no sponsor cost yet gains independent clinical data in its core MSS CRC indication and a third PD-1-bispecific combination for ADG126. That broadens the case for muzastotug as a combination backbone, but the readout is years away and the trial tests a combination Adagene does not control, so near-term cash flow is unchanged.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADAG was trading at $1.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107.4M. The 52-week trading range was $1.42 to $4.85. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.